Dr. Euan Ashley - 30 Oct 2026 Form 4 Insider Report for DEXCOM INC (DXCM)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Nov 2026, 17:01:14 UTC
Prior SEC filing
01 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christophe Cantenot, as Attorney-in-Fact for Dr. Euan Ashley
Filing notes and source

Key filing fact

Dr. Euan Ashley filed Form 4 for DEXCOM INC (DXCM) on 03 Nov 2026.

Key facts

  • This page summarizes Dr. Euan Ashley's Form 4 filing for DEXCOM INC (DXCM).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 03 Nov 2026, 17:01.

Change

  • Previous filing in this sequence was filed on 01 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002092523 Primary reporting owner

Ashley Euan A.

Relationship
Director
Address
6340 SEQUENCE DRIVE, SAN DIEGO
Signature
/s/ Christophe Cantenot, as Attorney-in-Fact for Dr. Euan Ashley
Signature date
03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DXCM transaction

Common Stock

Gift

Transaction value
Shares
-2,389
Change %
-19%
Price
$0.000000*
Shares after
10,342
Date
30 Oct 2026
Ownership
Direct
Footnotes
F1, F2
DXCM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,389
Date
30 Oct 2026
Ownership
By Trust
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents unvested restricted stock units, 5,565 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 4,777 of which were granted on October 24, 2025 and shall vest through October 24, 2028.

Footnote F2

On October 30, 2026, the Reporting Person transferred 2,389 shares of the Issuer's common stock to the Ashley Family Revocable Living Trust for no consideration.

Footnote F3

Shares are held by the Ashley Family Revocable Living Trust, with respect to which the Reporting Person and the Reporting Person's spouse are co-trustees.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .